Additionally, multivalent conjugates, such as bispecific ADCs like AfHER2-lFGF2-vcMMAE, target both FGFR1 and HER2 in breast cancer, offering a promising new treatment approach [123]. The gene discussed is ERBB2; the disease is breast carcinoma.